Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

5-Azacytidine/5-Azacitidine.

Müller AM, Florek M.

Recent Results Cancer Res. 2014;201:299-324. doi: 10.1007/978-3-642-54490-3_19. Review.

PMID:
24756801
2.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
3.

Decitabine.

Hackanson B, Daskalakis M.

Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18. Review.

PMID:
24756800
4.

5-Azacytidine/Azacitidine.

Müller A, Florek M.

Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11. Review.

PMID:
20072837
5.

More is better: combination therapies for myelodysplastic syndromes.

Ornstein MC, Mukherjee S, Sekeres MA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):22-31. doi: 10.1016/j.beha.2014.11.002. Epub 2014 Nov 11. Review.

PMID:
25659727
6.

5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.

Diamantopoulos P, Zervakis K, Papadopoulou V, Iliakis T, Kalala F, Giannakopoulou N, Rougala N, Galanopoulos A, Bakarakos P, Variami E, Dimitrakopoulou A, Viniou NA.

Anticancer Res. 2015 Sep;35(9):5141-7.

PMID:
26254419
7.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
8.

Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Scott LJ.

Drugs. 2016 May;76(8):889-900. doi: 10.1007/s40265-016-0585-0. Review.

PMID:
27193945
9.

The role of azacitidine in the treatment of myelodysplastic syndromes.

Abdulhaq H, Rossetti JM.

Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. Review.

PMID:
18042004
10.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

11.

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

Platzbecker U, Germing U.

Leukemia. 2013 Sep;27(9):1813-9. doi: 10.1038/leu.2013.140. Epub 2013 May 6. Review.

PMID:
23644421
12.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.

Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.

PMID:
23519388
13.

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Itzykson R, Fenaux P.

Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411. Review. French.

14.

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S.

Leukemia. 2006 Feb;20(2):212-7.

PMID:
16357841
16.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
17.

Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.

Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1.

PMID:
24220615
18.

Treatment of higher-risk myelodysplastic syndrome.

Garcia-Manero G.

Semin Oncol. 2011 Oct;38(5):673-81. doi: 10.1053/j.seminoncol.2011.07.001. Review.

PMID:
21943674
19.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
20.

Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.

Szmigielska-Kapłon A, Robak T.

Curr Cancer Drug Targets. 2011 Sep;11(7):837-48. Review.

PMID:
21762079

Supplemental Content

Support Center